G17S (p.Gly17Ser) variant of FBN2 (Fibrillin-2)

G17S (p.Gly17Ser) in FBN2 (Fibrillin-2) is a missense change. Clinical records from EBI and UniProt describe it as likely benign. The available variant effect predictions contribute to a CATVariant prioritization score of 0.27 / 1. The record also includes population frequency data, published literature, and structural context.

G17S (p.Gly17Ser) variant details